Answer
The oral solution is licensed for specified forms of polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in children aged 2 years and older. The prolonged-release formulation is not licensed for children.
Sources for this answer
- XELJANZ 1 mg/mL oral solution — Current selected SmPCemc · Summary of Product Characteristics
- XELJANZ 11 mg prolonged release tablets — Current selected SmPCemc · Summary of Product Characteristics